Lupin is hoping to turn the corner in the US, led by key approvals of generic versions of Renexa and Synthroid in place and a possible launch of Albuterol MDI in second half of FY20.from Moneycontrol Business News https://ift.tt/2SDta7v
Monday, March 4, 2019
Lupin#39;s Nilesh Gupta says new launches will help turn the corner in coming quarters
Lupin is hoping to turn the corner in the US, led by key approvals of generic versions of Renexa and Synthroid in place and a possible launch of Albuterol MDI in second half of FY20.from Moneycontrol Business News https://ift.tt/2SDta7v
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment